Evidence map›Paper›PMID 42565546›Full record

ArticleJournal of addiction medicine2026

What Dose of Methamphetamine Do Regular Consumers Use Daily? Estimating Oral Amphetamine Milligram Equivalents.

Joseph R Friedman, Adam J Koncsol, Caitlin A Molina, Ruby Romero, Jasmine Feng, Michelle Poimboeuf, Morgan E Godvin, Siddarth Puri, Carla Marienfeld, Chelsea L Shover

Abstract read
In one paragraph

Article in Journal of addiction medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Joseph R Friedman
Adam J Koncsol
Caitlin A Molina
Ruby Romero
Jasmine Feng
Michelle Poimboeuf
Morgan E Godvin
Siddarth Puri
Carla Marienfeld
Chelsea L Shover

Funding

NRSA Training CoreTL1TR001883 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALEX BUI, Nina Thawata Harawa · 2016 to 2026
$8.6M
A binational cohort of the intersection between substance use, HIV, and associated comorbidities among people who inject drugs in San Diego, CA U01DA063078 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Britt Skaathun, Steffanie A Strathdee · 2025 to 2026
$4.9M
Adoption and scale-up of long-acting medications for opioid use disorder by U.S. clinicians.K01DA050771 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOVER, CHELSEA LEIGH · 2021 to 2025
$893k
NCATS NIH HHS TL1 TR001883NIDA NIH HHS K01 DA050771NIDA NIH HHS U01 DA063078
6 · The paper itself

Abstract

objectivesThe purity, accessibility, and affordability of illicit methamphetamine have increased in recent decades, which has been linked to rising rates of methamphetamine-involved overdoses, psychosis, cardiovascular events, and other health consequences. Nevertheless, information about the quantity of methamphetamine used by regular consumers has been limited, despite the potential clinical utility of exposure quantification.

methodsFrom August 2024 to April 2026, self-reported daily methamphetamine consumption was assessed among n = 94 individuals in Los Angeles County. Methamphetamine samples (n = 256) were analyzed for purity using liquid chromatography-mass spectrometry. Bioavailability by route of administration and stimulant equivalency were obtained from the literature. A simulation model leveraging bootstrapping with 1,000,000 draws was used to estimate oral amphetamine milligram equivalents (AME).

resultsThe average reported methamphetamine consumption was 1.09 g daily (95% prediction interval: 0.07-4.00). Average purity was 84.52% (95% PI: 14.90%-100.00%). Given estimated average bioavailability of 66.41% (95% PI: 39.35%-85.24%), the average consumer used an estimated 1432.54 AME daily (95% PI: 35.74-6973.05).

conclusionsWe estimate that consumers of methamphetamine in Los Angeles use an average daily stimulant dose (nearly 1500 oral AME) about 25-fold higher than the maximum typical recommended clinical dose of mixed amphetamine salts (60 mg). This may help contextualize why prescription stimulant treatment trials using substantially lower doses have shown limited efficacy. Given this high dose, these findings shed light on the rising incidence of methamphetamine-related sequelae, such as psychosis, cardiovascular complications, and sudden death. Although exposure quantification is commonplace for alcohol and tobacco use disorders, uncertainties in illicit drug markets have complicated this practice for most illicit drugs. This study supports leveraging emerging information from drug checking programs so that clinicians can approximate exposure quantification.

Indexed as

drug checkingexposure quantificationmethamphetamine use disorderrisk stratification

Identifiers

PMID42565546
PMCPMC13508268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.